Novel Serum Biomarkers to Differentiate Cholangiocarcinoma from Benign Biliary Tract Diseases Using a Proteomic Approach

Figure 1

Schematic diagram of the experimental workflow. Serum samples were collected from 17 BBTD patients and 19 CCA patients, which were then subjected to routine ELISA for CEA and CA19-9. Purified proteins from these samples were then separated by SDS-PAGE. After migration, entire lanes were divided into 5 sections, which were excised into slices and treated with in-gel digestion. The resulting tryptic peptides were subjected to reverse-phase LC-MS/MS, from which the mass spectrometric results were then analyzed for protein identification and quantification. The relative quantitation ratios were subjected to statistical analyses and 6-fold cross-validation to retrieve the DE proteins between BBTDs and CCA.